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OBJECTIVES: To measure cost of care in cardiologic
departements for inpatients with decompensated, systolic
heart failure and to study major cost drivers. METHODS:
In 2000, a multicentric observational study was set up
within 8 cardiology departments in France. Patients over
18, hospitalized with decompensated systolic heart failure
(HF), and LVEF < 45% were prospectively included. Data
were collected up to ﬁnal discharge from the department.
Cost of lab tests, procedures, blood products and phar-
macy were extracted from ofﬁcial guidelines or public
hospital sources. Other patients’ stay ﬁxed costs, includ-
ing staff and overheads, were averaged from hospital
sources. Factorial analysis was performed on patients’
socio-demographic and clinical caracteristics. RESULTS:
Two hundred twenty-one patients were included, with
mean age 66 years, 62% male. Main diagnoses were coro-
nary heart disease (CHD): 48%, and dilated cardiomy-
opathy: 28%. Average length of stay (LOS) in cardiologic
departement was 12.4 days. Average total cost was €5770
(sd: €3975) for each patient. Factors linked to higher costs
were: transfert from an other department, emergency
admittance, new diagnosis, no previous treatment, and
ﬁrst hospitalization. Factorial analysis identiﬁed 3 clus-
ters: one cluster of elderly patients, mean age 77 years,
higher LVEF (36%), 60% previously known HF, two
clusters with younger patients: mean age 64 years, mainly
with CHD; patients in cluster 2 had 97% HF already
known and 88% former hospitalization, lower LVEF
(26%), whereas in cluster3 100% new diagnosis of HF,
high proportion of ICU stay. Hospitalization costs were
higher (p < 0.01) in cluster 3 (€6792) than in cluster 2
(€5692) or 1 (€5016), without difference in LOS. Main
cost difference was linked to invasive cardio-vascular pro-
cedures (€1177 in cluster 3, versus €266 in other clusters,
p < 0.001). CONCLUSION: Higher costs for patients
with decompensated heart failure were related to ﬁrst
hospitalization and new diagnosis, intensive cardiac pro-
cedures, mainly for coronary artery disease. Hospitaliza-
tion costs were lower for relapses.
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OBJECTIVE: To generate estimates of the cost-
effectiveness of combined ACE-inhibitor and calcium
antagonist therapy (Tarka) versus ACE-inhibitors (usual
care) in patients with heart failure after myocardial
infarction in the US health care setting. METHODS:
Markov process analysis techniques were used to model
the health eonomic outcomes. Data on probabilities of
clinical events were derived from clinical trial data and
other published literature; units of health care utilization
were derived from the literature and the HCUP database;
prices/tariffs were derived from ofﬁcial lists. Study per-
spective was that of the third party payer. RESULTS: An
analysis over the Tarka trial period shows that Tarka
decreases the costs from US$24,567 to US$19,907. The
mortality for Tarka is at least equal to usual care (1.96%
versus 2.04%) and consequently Tarka can be considered
dominant over usual care. Tarka remains cost saving over
a follow-up of 5 and 10 years. The cost saving are respec-
tively US$5120 and US$3642. The use of Tarka also leads
to substantial reductions in cumulative mortality, which
are respectively 9.4% and 11.7% over 5 and 10 years.
The lifetime model shows that the use of Tarka leads to
an incremental cost-effectiveness ratio of US$1730 per
life year gained. Probabilistic sensitivity analysis showed
that the probability is 55% that the incremental cost
effectiveness ratio of Tarka is less than US$5000 per life
year gained, while the incremental cost effectiveness ratio
will always be less than US$10,000. CONCLUSION: The
results showed that the favourable clinical beneﬁt of
Tarka results in positive short and long-term health eco-
nomic beneﬁts.
PCV34
COST-EFFECTIVENESS OF FRACTIONAL 
FLOW RESERVE TESTING TO GUIDE
PERCUTANEOUS CORONARY INTERVENTION
IN THE DRUG-ELUTING STENT ERA: A
DECISION ANALYSIS
Siebert U1, Greenberg D1, Kuntz KM2, Cohen DJ1
1Harvard University, Boston, MA, USA; 2Harvard School of
Public Health, Boston, MA, USA
OBJECTIVE: Pressure-based fractional ﬂow reserve
(FFR) is an invasive test for assessing the functional 
signiﬁcance of intermediate coronary stenoses. Previous
studies have found that FFR testing to guide percutaneous
coronary intervention (PCI) is cost-effective. In this study
we evaluate the impact of using drug-eluting stents (DES)
on this decision. METHODS: We developed a Markov
model to compare the long-term costs and outcomes of 2
strategies for patients with indeterminate coronary steno-
sis scheduled for PCI: 1) Universal PCI (UNIV) without
FFR testing, and 2) FFR testing followed by PCI only for
those with FFR < 0.75 (TEST). Base-case: 60-year-old
man under the optimistic assumption (for UNIV) that 
relative mortality reduction with revascularization is
independent of functional signiﬁcance. Data: long-term
clinical outcomes of PCI and medical management includ-
ing recurrence rates, disease progression, and quality of
life based on published literature. Based on ﬁxed effects
meta-analysis, we estimated that DES reduce clinical
restenosis rates by 79% compared with bare metal stents
(BMS). Perspective: societal. Discounting: 3% per year.
RESULTS: For the case of BMS, UNIV increased costs by
$2800/patient and improved outcome by 12 quality-
adjusted life days (QALD), yielding an incremental cost-
